

## CLAIMS

Sub A1  
5 1. A cilostazol preparation having a capability of dissolving cilostazol even at the lower portion of the digestive tract, which comprises incorporating a fine powder of cilostazol as an active ingredient into a dispersing and/or solubilizing agent.

10 2. The cilostazol preparation according to claim 1, wherein said dispersing and/or solubilizing agent is selected from the group consisting of a water-soluble polymer, a surfactant and a mixture thereof.

15 3. The cilostazol preparation according to claim 2, wherein said fine powder of cilostazol is a fine powder having average particle diameter of about 10  $\mu$ m or less.

Sub A2  
20 4. The cilostazol preparation according to claim 3, wherein said dispersing and/or solubilizing agent is incorporated within a range from 0.005 to 50 parts by weight based on 1 part by weight of cilostazol.

25 5. The cilostazol preparation according to claim 3 or 4, wherein said dispersing and/or solubilizing agent is selected from the group consisting of a water-soluble polymer,

a surfactant and a mixture thereof.

6. The cilostazol preparation according to claim 5,  
wherein said dispersing and/or solubilizing agent is a  
5 surfactant.

7. The cilostazol preparation according to claim 6,  
wherein said surfactant is an alkyl sulfate salt.

8. The cilostazol preparation according to claim 5,  
wherein said fine powder of cilostazol is a fine powder having  
average particle diameter of about 7  $\mu\text{m}$  or less.

9. The cilostazol preparation according to claim 8,  
wherein said dispersing and/or solubilizing agent is  
15 incorporated within a range from 0.01 to 10 parts by weight  
based on 1 part by weight of cilostazol.

10. The cilostazol preparation according to claim 8,  
20 wherein said fine powder of cilostazol is a fine powder having  
average particle diameter of about 5  $\mu\text{m}$  or less.

11. The cilostazol preparation according to claim 8,  
wherein said dispersing and/or solubilizing agent is a  
25 surfactant.

Sub  
A4  
12. The cilostazol preparation according to claim 11,  
wherein said fine powder of cilostazol is a fine powder having  
average particle diameter of about 5  $\mu$ m or less.

5 13. The cilostazol preparation according to claim 12,  
wherein said surfactant is an alkyl sulfate salt.

10 14. The cilostazol preparation according to claim 13,  
wherein said alkyl sulfate salt is a sodium lauryl sulfate.

15 15. A process for improving absorbability of a slightly  
soluble drug which is hard to be absorbed at the lower portion  
of the digestive tract, which comprises forming said slightly  
soluble drug as an active ingredient into a fine powder and  
improving dispersibility and/or solubility of said slightly  
soluble drug.

20 16. The process for improving the absorbability at the  
lower portion of the digestive tract according to claim 15,  
wherein a dispersing and/or solubilizing agent is  
incorporated into said slightly soluble drug thereby to  
improve the dispersibility and/or solubility of said slightly  
soluble drug.

25 17. The process for improving the absorbability at the

lower portion of the digestive tract according to claim 15, wherein said slightly soluble drug as an active ingredient is cilostazol.

5 18. The process for improving the absorbability at the lower portion of the digestive tract according to claim 17, wherein a dispersing and/or solubilizing agent is incorporated into said slightly soluble drug thereby to improve the dispersibility and/or solubility of said slightly  
10 soluble drug.

19. The process for improving the absorbability at the lower portion of the digestive tract according to claim 17, wherein said fine powder of cilostazol is a fine powder having  
15 average particle diameter of about 10  $\mu$ m or less.

20. A sustained release preparation of cilostazol which contains any one of cilostazol preparations described in claims 1 to 14.

20

21. The sustained release preparation according to claim 20, which has a capability of releasing cilostazol even at the lower portion of the digestive tract.

25 22. The sustained release preparation according to

005503 011817 200410 220550

Sub  
AS

claim 21, wherein the cilostazol preparation is coated with a sustained release material.

23. The sustained release preparation according to claim 21, which is a dry coated tablet comprising a sustained release outer layer portion containing cilostazol, and a sustained release core tablet containing a cilostazol preparation, wherein a solubility of said core tablet is more rapid than that of said outer layer portion.

24. The sustained release preparation according to claim 21, which is a tablet containing core granules wherein sustained release core granules containing a cilostazol preparation are coated with an enteric material and further said sustained release core granules are compressed with an outer layer portion containing cilostazol.

25. The sustained release preparation according to claim 21, which is a capsule comprising granules coated with an enteric material wherein said granules contain a cilostazol preparation and rapid release powders or tablets containing cilostazol.

26. The sustained release preparation according to claim 21, which is a multiple-unit type preparation wherein

at least more than 2 of sustained release small tablets containing a cilostazol preparation are contained.

27. A fine powder of cilostazol having average particle  
5 diameter of about 10  $\mu\text{m}$  or less, which is for a starting  
material of a sustained release preparation of cilostazol.

28. The fine powder of cilostazol according to claim  
27, which has an average particle diameter of about 5  $\mu\text{m}$  or  
10 less.

add  
At

005502.0100  
00310 320550